The risks of major head and neck surgery in the aged population [PDF]
William F. McGuirt+3 more
openalex +1 more source
Presbycusis: Pathology, Signal Pathways, and Therapeutic Strategy
In ARHL, the stria vascularis, acting as a cochlear battery, gradually loses its ability to maintain the endocochlear potential, leading to impaired hair cell function and progressive hearing loss. Single‐cell sequencing reveals age‐related cellular changes in the cochlea, providing insights into the underlying mechanisms of aging and potential ...
Xiaoxu Zhao+12 more
wiley +1 more source
HPV-Driven Head and Neck Cancer: The European Perspective. [PDF]
Golusiński W+3 more
europepmc +1 more source
Chemical infusion for extensive head and neck tumour followed by surgery
Simon Fredricks, S. BARON HARDY
openalex +1 more source
Paragangliomas of the head and neck region.A clinical study of 69 patients [PDF]
Ernest E. Lack+3 more
openalex +1 more source
Rational Design of Inner Ear Drug Delivery Systems
Hearing loss is a common disease affecting many people, and inner ear lesions are one of the most important causes. This review focuses on the treatment of inner ear hearing loss by drug delivery systems. It includes the current methods and technologies developed, and it predicts possible directions.
Xiayidan Maimaitikelimu+5 more
wiley +1 more source
Sex Differences in Head and Neck Carcinoma - A Retrospective Study on 1115 Head and Neck Carcinoma Patients in Austria. [PDF]
Kofler B+11 more
europepmc +1 more source
175. Pursuit Motion in Patients with Head and Neck Injuries
Yoshinao HUKADO+3 more
openalex +2 more sources
Combination therapy of advanced head and neck cancer.Induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy [PDF]
Victor L. Randolph+6 more
openalex +1 more source
A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer
Overcoming EGFR‐TKI resistance remains a critical challenge in NSCLC treatment. This study identifies CMTM6 as a key regulator of EGFR stability and demonstrates that a novel anti‐CMTM6 nanobody disrupts the CMTM6‐EGFR interaction. Targeting CMTM6 restores EGFR degradation, suppresses tumor growth, and confers therapeutic benefit in both CDX and PDX ...
Lu Xia+18 more
wiley +1 more source